Literature DB >> 19125350

Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy.

Germaine Pierre1, Kenneth Setchell, Jacqueline Blyth, Mary Anne Preece, Anupam Chakrapani, Patrick McKiernan.   

Abstract

Cerebrotendinous xanthomatosis (CTX) OMIM#213700 is a rare disorder of bile acid synthesis caused by deficiency of the enzyme sterol 27-hydroxylase. It results in deficiency of bile acids and accumulation of abnormal bile alcohols and accelerated cholesterol synthesis. CTX usually presents in the second or third decade with slowly progressive neurological dysfunction, cerebellar ataxia and premature atherosclerosis. Treatment with bile acid supplementation improves but does not completely reverse the neurological signs and symptoms. However, CTX is now known to be associated with a period of neonatal cholestasis. If it is diagnosed at this point, treatment may prevent the onset of neurological problems. We present the case histories and developmental findings in two affected siblings treated from infancy. We plan to continue regular neurodevelopmental reviews.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19125350     DOI: 10.1007/s10545-008-0815-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  20 in total

Review 1.  Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature.

Authors:  M Kuriyama; J Fujiyama; H Yoshidome; S Takenaga; K Matsumuro; T Kasama; K Fukuda; T Kuramoto; T Hoshita; Y Seyama
Journal:  J Neurol Sci       Date:  1991-04       Impact factor: 3.181

Review 2.  Defects in bile acid biosynthesis--diagnosis and treatment.

Authors:  Kenneth D R Setchell; James E Heubi
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-07       Impact factor: 2.839

Review 3.  Bile acid biosynthesis.

Authors:  D W Russell; K D Setchell
Journal:  Biochemistry       Date:  1992-05-26       Impact factor: 3.162

4.  Cerebrotendinous xanthomatosis: need for early diagnosis.

Authors:  K Muhammed; G Nandakumar; S Saritha
Journal:  Indian J Dermatol Venereol Leprol       Date:  2006 Sep-Oct       Impact factor: 2.545

5.  Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system.

Authors:  J H Menkes; J R Schimschock; P D Swanson
Journal:  Arch Neurol       Date:  1968-07

6.  Cerebrotendinous xanthomatosis in three siblings from a Chinese family.

Authors:  K F Ko; K W Lee
Journal:  Singapore Med J       Date:  2001-01       Impact factor: 1.858

7.  Four novel mutations of sterol 27-hydroxylase gene in Italian patients with cerebrotendinous xanthomatosis.

Authors:  R Garuti; M A Croce; R Tiozzo; M T Dotti; A Federico; S Bertolini; S Calandra
Journal:  J Lipid Res       Date:  1997-11       Impact factor: 5.922

8.  Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.

Authors:  M Kuriyama; Y Tokimura; J Fujiyama; Y Utatsu; M Osame
Journal:  J Neurol Sci       Date:  1994-08       Impact factor: 3.181

9.  Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.

Authors:  T Nakamura; Y Matsuzawa; K Takemura; M Kubo; H Miki; S Tarui
Journal:  Metabolism       Date:  1991-07       Impact factor: 8.694

10.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

View more
  16 in total

1.  Children with cataract and chronic diarrhoea: cerebrotendinous xanthomatosis.

Authors:  J R M Cruysberg
Journal:  J Inherit Metab Dis       Date:  2009-03-09       Impact factor: 4.982

2.  A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios.

Authors:  Frédéric M Vaz; Albert H Bootsma; Willem Kulik; Aad Verrips; Ron A Wevers; Peter C Schielen; Andrea E DeBarber; Hidde H Huidekoper
Journal:  J Lipid Res       Date:  2017-03-17       Impact factor: 5.922

3.  Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment.

Authors:  Andrea E DeBarber; Limor Kalfon; Ayalla Fedida; Vered Fleisher Sheffer; Shani Ben Haroush; Natalia Chasnyk; Efrat Shuster Biton; Hanna Mandel; Krystal Jeffries; Eric S Shinwell; Tzipora C Falik-Zaccai
Journal:  J Lipid Res       Date:  2018-08-22       Impact factor: 5.922

4.  A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Gian Nicola Gallus; Maria Teresa Dotti; Antonio Federico
Journal:  J Inherit Metab Dis       Date:  2014-01-18       Impact factor: 4.982

Review 5.  An Overview of the Current State and the Future of Ataxia Treatments.

Authors:  Kimberly Tsu Kwei; Sheng-Han Kuo
Journal:  Neurol Clin       Date:  2020-02-27       Impact factor: 3.806

6.  Nationwide survey on cerebrotendinous xanthomatosis in Japan.

Authors:  Yoshiki Sekijima; Shingo Koyama; Tsuneaki Yoshinaga; Masayoshi Koinuma; Yuji Inaba
Journal:  J Hum Genet       Date:  2018-01-10       Impact factor: 3.172

7.  Autosomal recessive adult onset ataxia.

Authors:  Nataša Dragašević-Mišković; Iva Stanković; Andona Milovanović; Vladimir S Kostić
Journal:  J Neurol       Date:  2021-09-09       Impact factor: 4.849

8.  CYP27A1 mutation in a case of cerebrotendinous xanthomatosis: A case report.

Authors:  Zhao-Ran Li; Yu-Ling Zhou; Qi Jin; Yin-Yin Xie; Hong-Mei Meng
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

9.  Analysis of factors affecting the prognosis of neonatal cholestasis.

Authors:  Pengfei Liu; Lin Guo; Lanfeng Huang; Dewei Zhao; Ruixin Zhen; Xiaoning Hu; Xiaolin Yuan
Journal:  Int J Clin Exp Med       Date:  2015-05-15

10.  A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns.

Authors:  Andrea E DeBarber; Jenny Luo; Michal Star-Weinstock; Subhasish Purkayastha; Michael T Geraghty; John Pei-Wen Chiang; Louise S Merkens; Anuradha S Pappu; Robert D Steiner
Journal:  J Lipid Res       Date:  2013-11-02       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.